Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents
Beteiligte Einrichtungen
Abstract
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma characterized by signalling from constitutively activated ALK fusion proteins. Most children and adolescents present in advanced stages, often with extranodal disease and B symptoms. The current front-line therapy standard of six cycles polychemotherapy reaches an event-free survival of 70%. The strongest independent prognostic factors are minimal disseminated disease and early minimal residual disease. At relapse, ALK-inhibitors, Brentuximab Vedotin, Vinblastine, or second line chemotherapy are effective re-inductions. Survival at relapse exceeds 60-70% with consolidation according to the time of relapse (Vinblastine monotherapy or allogeneic hematopoietic stem cell transplantation) so that the overall survival reaches 95%. It needs to be shown whether check-point inhibitors or long-term ALK-inhibition may substitute for transplantation. The future necessitates international cooperative trials testing whether a shift of paradigm to a chemotherapy-free regimen can cure ALK-positive ALCL.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 1521-6926 |
DOIs | |
Status | Veröffentlicht - 03.2023 |
Anmerkungen des Dekanats
Copyright © 2023 Elsevier Ltd. All rights reserved.
PubMed | 36907641 |
---|